Insider Trading May 11, 2026 08:28 PM

Astera Labs CEO Executes $28 Million Stock Sale via Pre-Arranged Trading Plan

Jitendra Mohan liquidates 140,951 shares amid significant year-over-year stock price appreciation and strong quarterly earnings performance.

By Leila Farooq ALAB

Jitendra Mohan, the Chief Executive Officer and a director of Astera Labs, Inc. (NASDAQ:ALAB), has completed a sale of common stock totaling approximately $28.01 million. The transaction, which took place on May 7, 2026, involved the disposal of 140,951 shares. This divestment was conducted through an automated process under a Rule 10b5-1 trading plan that Mr. Mohan had established on December 1, 2025.The liquidation occurred in several separate transactions, with weighted average prices falling between $199.3269 and $205.7363 per share. On an individual basis, the transaction prices for these sales ranged from a low of $199.0000 to a high of $205.9700. The shares sold were held indirectly by a living trust where Mr. Mohan serves as a trustee. While he maintains a pecuniary interest in these securities, Mr. Mohan disclaims beneficial ownership of the shares.

Astera Labs CEO Executes $28 Million Stock Sale via Pre-Arranged Trading Plan
ALAB

Key Points

  • Astera Labs reported 93% year-over-year revenue growth to $308.4 million.
  • The company's Q1 2026 non-GAAP diluted EPS of $0.61 beat expectations by 238.89%.
  • CEO Jitendra Mohan sold approximately $28 million in stock via a pre-set 10b5-1 plan.

Astera Labs, Inc. (NASDAQ:ALAB) recently saw significant insider activity as CEO and director Jitendra Mohan sold 140,951 shares of common stock on May 7, 2026. The total value realized from these sales reached roughly $28.01 million. These transactions were not discretionary in the immediate sense, but were instead executed automatically according to a Rule 10b5-1 trading plan that was adopted by Mr. Mohan back on December 1, 2025.

The execution of these sales involved multiple transactions at varying prices. The weighted average price per share for the total block was between $199.3269 and $205.7363, while specific transaction prices ranged from $199.0000 to $205.9700. All of the shares sold were held indirectly via a living trust in which Mr. Mohan acts as a trustee; he disclaims beneficial ownership except for his pecuniary interest.


Market Context and Financial Performance

This insider transaction follows a period of substantial growth for Astera Labs, with the company's stock surging 158% over the last twelve months. At the time of reporting, the stock was trading at $207.35. However, analysis from InvestingPro suggests that the current stock price may be overvalued relative to its Fair Value, noting that the company appears on a list of most overvalued entities.

The sale also follows an exceptionally strong first quarter for 2026. Astera Labs reported financial results that exceeded market expectations significantly. The company posted a non-GAAP diluted earnings per share (EPS) of $0.61, which represents a 238.89% surprise compared to the anticipated $0.18. Additionally, quarterly revenue climbed to $308.4 million, marking a 93% increase over the corresponding period from the previous year.


Current Holdings and Ownership Structure

Despite this sale, Mr. Mohan maintains significant exposure to Astera Labs through various holdings:

  • Indirect Trust Holdings: Following the May 7 transactions, his indirect holdings via the living trust total 3,929,183 shares.
  • Estate Planning Trusts: He holds additional interests through several other trusts, including one holding 699,999 shares, two 2021 trusts holding 700,000 shares each, and two 2022 trusts holding 450,001 shares each.
  • Direct Ownership: Mr. Mohan personally holds 1,452,739 shares of Astera Labs common stock.

Key Insights and Market Impact

Key Points:

  • Strong Revenue Trajectory: The 93% year-over-year revenue growth indicates rapid scaling within the semiconductor or hardware technology sectors.
  • Earnings Beat: The massive surprise in non-GAAP diluted EPS suggests high operational leverage and efficiency during the first quarter of 2026.
  • Institutional Valuation Scrutiny: As analysts reassess valuations following these results, the technology sector may see shifts in how high-growth companies are priced relative to their intrinsic value.

Risks and Uncertainties:

  • Valuation Risk: With the stock being identified as potentially overvalued relative to its Fair Value, there is a risk of price correction in the equity markets.
  • Growth Sustainability: While recent results were outstanding, investors face uncertainty regarding how long the current rate of revenue and earnings growth can be maintained in upcoming quarters.

Risks

  • The stock is currently characterized as overvalued relative to its Fair Value.
  • Future performance remains an uncertainty as investors wait for upcoming quarterly results.

More from Insider Trading

Edwards Lifesciences CEO Executes Multi-Million Dollar Share Sale via Pre-Set Trading Plan May 12, 2026 Covista CFO Executes $1.26 Million Stock Sale via Pre-Scheduled Trading Plan May 12, 2026 Covista Executive Executes Planned Share Sale Amidst Corporate Growth and Financial Restructuring May 12, 2026 Covista Executive Executes $1.22 Million Stock Sale Under Pre-Planned Trading Program May 12, 2026 Ameriprise Financial Director Executes Stock Sale Amid Strong Earnings Performance May 12, 2026